Company intelligence / Profile preview

MS Biotec

Wamego, Kansas, United Statesmsbiotec.com ↗

Ownership: Private
Employees: ~70
Development stage: Other

Overview

MS Biotec has commercialized microbial products containing the rumen-native lactic acid-utilizing bacterium Megasphaera elsdenii (Mega e) for beef feedlot and dairy cattle, marketed in Lactipro-branded products and used to regulate rumen pH and support a healthy rumen environment in commercial herds since 2010.[1][2]

Therapeutic areas: OtherGastroenterology
Modalities: Microbial therapyLive biotherapeutic product therapy
Industry: Veterinary

Drug pipeline

2 assets

Multimin 90

Commercial

Indications: Trace mineral supplementation in cattle

1 more asset in the full pipeline.

Request access →

Partnerships

Axiota Animal Health (integration as microbial technology center and co-owner of patent for Megasphaera elsdenii NCIMB 41125)[1]

Beyond the preview

Go deeper on MS Biotec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS Biotec.

Explore the full profile